LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

20.03 6.71

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.73

Максимум

20.03

Ключови измерители
By Trading Economics
Приходи	4.8M -36M
Продажби	6.1M 116M
Марж на печалбата	-30.977
Служители	1,869
EBITDA	24M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+110.93% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-944M 2.1B
Предишно отваряне	13.32
Предишно затваряне	20.03

Настроения в новините

By Acuity

25%

75%

45 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.02.2026 г., 22:17 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16.02.2026 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Bar Very High For Asset Deals

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16.02.2026 г., 22:35 ч. UTC

Пазарно говорене

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16.02.2026 г., 22:02 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16.02.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: China's Economy Resilient; India Continues to Outperform

16.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16.02.2026 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16.02.2026 г., 21:46 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Interim Dividend Represents 60% Payout Ratio

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16.02.2026 г., 21:45 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16.02.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16.02.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16.02.2026 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16.02.2026 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16.02.2026 г., 21:41 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

110.93% нагоре

12-месечна прогноза

Среден 42.25 USD 110.93%

Висок 58 USD

Нисък 35 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

45 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.